Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency

NCT05907746 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

7

Enrollment

NIH

Sponsor class

Conditions

GATA2
Immunodeficiency

Interventions

DRUG: Mycophenolate Mofetil
DRUG: Tacrolimus
DRUG: Post-Transplant Cyclophosphamide
RADIATION: Total Body Irradiation
PROCEDURE: Hematopoietic Cell Transplant
DRUG: Briquilimab
DRUG: Cyclophosphamide
DRUG: Fludarabine

Sponsor

National Cancer Institute (NCI)